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Abstract
Purpose
Patients with acute myocardial infarction (AMI) and respiratory impairment may be treated
with either invasive or non-invasive mechanical ventilation (MV). However, there has been
little testing of non-invasive MV in the setting of AMI. Our objective was to evaluate the inci-
dence and associated clinical outcomes of patients with AMI who were treated with non-
invasive or invasive MV.
Methods
This was a retrospective observational study in which consecutive patients with AMI (n =
1610) were enrolled. The association between exclusively non-invasive MV, invasive MV
and outcomes was assessed by multivariable models.
Results
Mechanical ventilation was used in 293 patients (54% invasive and 46% exclusively non-
invasive). In-hospital mortality rates for patients without MV, with exclusively non-invasive
MV, and with invasive MV were 4.0%, 8.8%, and 39.5%, respectively (P<0.001). The
median lengths of hospital stay were 6 (5.8–6.2), 13 (11.2–4.7), and 28 (18.0–37.9) days,
respectively (P<0.001). Exclusively non-invasive MV was not associated with in-hospital
death (adjusted HR = 0.90, 95% CI 0.40–1.99, P = 0.79). Invasive MV was strongly associ-
ated with a higher risk of in-hospital death (adjusted HR = 3.07, 95% CI 1.79–5.26,
P<0.001).
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Conclusions
In AMI setting, 18% of the patients required MV. Almost half of these patients were treated
with exclusively non-invasive strategies with a favorable prognosis, while patients who
needed to be treated invasively had a three-fold increase in the risk of death. Future pro-
spective randomized trials are needed to compare the effectiveness of invasive and non-
invasive MV for the initial approach of respiratory failure in AMI patients.
Introduction
Approximately 17% of patients with acute myocardial infarction (AMI) typically experience
respiratory impairment due to decompensated heart failure [1]. Depending on the severity of
the respiratory impairment, patients may be treated with either invasive or non-invasive
mechanical ventilation (MV) [2,3]. Prior studies have shown that nearly 8% of patients with
AMI are treated with invasive MV during their hospital stay [3], forming a very high-risk sub-
group with almost 50% short-term mortality rates [4].
On the other hand, several trials and meta-analyses have demonstrated that non-invasive
MVmay be useful for the treatment of cardiogenic pulmonary edema [5,6]. Both continuous
positive airway pressure and bi-level positive airway pressure ventilation, by improving gas
exchange and hemodynamics, have been proven effective and safe in reducing the need for
endotracheal intubation [7]. Unfortunately, most of these studies were not performed in
acutely ischemic patients, and only small trials have tested non-invasive MV in the setting of
AMI [8,9].
Given the limitations of the contemporary literature, the objective of our study was to assess
the incidence and associated clinical outcomes of unselected AMI patients with respiratory fail-
ure requiring non-invasive or invasive MV.
Materials and Methods
Population
This was a retrospective observational study in which 1610 consecutive patients with ST-seg-
ment elevation myocardial infarction (STEMI) and non-STEMI were enrolled between 2004
and 2012.
AMI was defined according to international guideline criteria [10]: typical rise and gradual
fall of biochemical markers of myocardial necrosis (troponin or creatine kinase-MB) with at
least one of the following: 1) ischemic symptoms, 2) development of pathologic Q waves on the
electrocardiogram (ECG), 3) ECG changes indicative of ischemia (ST-segment elevation or
depression), or 4) coronary artery intervention (e.g., coronary angioplasty). The registry design,
methods, and main results have been reported previously [11].
Clinical characteristics and in-hospital outcomes were compared among three groups of
patients: (1) those who did not receive MV, (2) those treated exclusively with non-invasive
MV, and (3) those that required invasive MV. Patients who used both types of MV could have
used non-invasive MV as part of the initial treatment, before intubation, or as part of the MV
weaning protocol after endotracheal extubation. Data on the chronology of the use of invasive
and non-invasive MV in these patients was unavailable. Thus, patients treated initially with
non-invasive MV prior to intubation, or during respiratory weaning, were considered part of
the invasive MV group for the purposes of this analysis.
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myocardial infarction; ACE, angiotensin converting
enzyme; ARBs, angiotensin II receptor blockers.
The diagnosis of respiratory failure, the indication for MV, the timing of support initiation,
MV weaning strategies and all medical treatment decisions were determined by the medical
staff in charge. Non-invasive MV was performed routinely by a respiratory physiotherapist
with bi-level positive airway pressure according to standardized procedures. Noninvasive ven-
tilation was delivered by a total face mask, secured with head straps, coupled to a BIPAP
Vision™ (Respironics INC1, Pennsylvania, USA). For patients with a nasogastric tube, a seal
connector in the dome of the mask was used to minimize air leakage. After the mask was
attached to the patient, pressure support was set at 5 cmH20 to obtain an exhaled tidal volume
of 6 mL/kg of predicted body weight, a respiratory rate lower than 30 breaths per minute, atten-
uation of respiratory accessory muscle activity and achievement of patient’s comfort. Positive
end-expiratory pressure (PEEP) was initiated at 10 cm H2O and increased in steps of 2 to 3 cm
H2O up to 15 cm H2O until the FiO2 requirement was 60% or less. All ventilator settings could
be re-adjusted by the attending physician and by a chest physiotherapist, based on the results
of continuous oximetry, measurements of arterial blood gases (specially PaCO2 and pH) and
ventilator parameters (expiratory tidal volume, respiratory rate, and mask leakage) as well as
on patients’ comfort. Criteria for endotracheal intubation included failure to maintain an arte-
rial oxygen partial pressure (PaO2)> 60 mmHg or SpO2> 90% with an FiO2 equal to or
greater than 60%, PaCO2 higher than 60 mmHg with pH lower than 7.25, inability to protect
the airways or to manage copious tracheal secretions, hemodynamic or electrocardiographic
instability, inability to tolerate the face mask, inability to correct dyspnea and progression of
respiratory failure. Non-invasive MV success patients were maintained coupled to a BIPAP
vision continuously during a 24-hour period. Afterwards, parameters were re-adjusted based
on SpO2, arterial blood gas analysis (specially PaCO2 levels), ventilator parameters (expiratory
tidal volume, respiratory rate and mask leakage) and patient’s comfort. When FiO2 was lower
than 50%, respiratory rate lower than 30 breaths per minute, expiratory tidal volume higher
than 5 mL/kg of predicted body weight with a pressure support lower than 10 cm H2O and
PEEP lower than 8 cm H2O, non-invasive MV was discontinued and oxygen ventury mask of
50% initiated. If an oxygen ventury mask of 50% was well tolerated during a one-hour period, a
ventury mask of 50% was alternated with non-invasive MV (1 hour in ventury mask of 50%
and 3 hours in NIV) until the patient could stay spontaneously breathing. The maximal time
allowed on full non-invasive MV support was 24 hours. After 24 hours, patients who could not
stay for at least one hour on oxygen ventury mask was defined dependent on non-invasive MV
and were intubated and mechanically ventilated.
A research nurse team was specifically designated to measure all variables in this registry,
including daily reevaluation of data on MV.
The study protocol was conducted in accordance with the Declaration of Helsinki and was
approved by the Institutional Review Board of the Hospital Israelita Albert Einstein. The study
was granted a waiver for informed consent.
Statistical analysis
Baseline patient characteristics were summarized by ventilation modality. Continuous vari-
ables were expressed as mean ± standard deviation (SD) or medians with interquartile range.
Categorical variables were described as absolute and relative frequencies. Analysis of variance
or the Kruskal-Wallis test was used to compare numerical variables among ventilation modali-
ties. The chi-square test was used for categorical variable comparisons.
An adjusted Cox proportional hazards regression model was performed to assess the associ-
ation between both types of MV and in-hospital death, using a stepwise backward selection of
variables with entry/stay criteria of p< 0.10/ p< 0.05. Clinical characteristics were also
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considered to select variables for adjustment. Consequently, fourteen variables were selected by
this method: age, gender, diabetes, troponin peak levels, Killip classification on admission, left
ventricular ejection fraction (LVEF), body mass index (BMI), STEMI, previous stroke, use of
aspirin, thienopyridines, beta-blockers, angiotensin converting enzyme (ACE) inhibitors/
angiotensin II receptor blockers (ARBs) and coronary reperfusion for STEMI patients. All sta-
tistical tests were two-sided, and the criterion for statistical significance was P<0.05. All statis-
tical analyses were performed using SPSS statistical software version 20.0.
Results
Mechanical ventilation was used in 293 patients (18.2% of the overall population; 54% invasive
and 46% non-invasive). Baseline and treatment characteristics of the patients stratified by the
presence or modality of MV are described in Tables 1 and 2.
Compared with patients who did not use MV, both groups that used MV were older, more
often diabetics, had lower LVEF, higher Killip classification, higher TIMI risk scores and were
less treated with thienopyridines or coronary reperfusion. Moreover, the invasive MV sub-
group was less treated with aspirin, beta-blockers and ACE inhibitors/ARBs, compared with
patients who did not use MV. Compared to exclusively non-invasive MV subgroup, invasive
MV patients were younger and more frequently males, had more frequently STEMI, higher
rates of patients on Killip 4 classification, a numerically non-significant higher level of troponin
and were less treated with beta-blockers and ACE inhibitor/ARBs. Smoking, BMI, previous
AMI and COPD rates were similar among the three groups.
The median (25th–75th percentile) lengths of hospital stay were 6 (5.8–6.2), 13 (11.2–4.7),
and 28 (18.0–37.9) days, respectively (P<0.001). In-hospital mortality rates for patients with-
out MV, with exclusively non-invasive MV, and with invasive MV were 4.0%, 8.8%, and 39.5%,
respectively (P<0.001).
In the adjusted models (Table 3), compared with the subgroup without MV: (1) non-inva-
sive MV was not associated with in-hospital death (adjusted HR = 0.90, 95% CI 0.40–1.99,
P = 0.79); and (2) invasive MV was associated with a 3-fold increase in the risk of in-hospital
death (adjusted HR = 3.07, 95% CI 1.79–5.26, P<0.001). Adjusted survival curves according to
ventilation modality demonstrated an increased risk of in-hospital death in patients treated
with invasive MV (Fig 1).
Discussion
In our study, we found that among patients with AMI, 18.2% needed treatment with MV.
Approximately half of these patients were managed non-invasively. Patients treated exclusively
with non-invasive MV had a relatively favorable prognosis, while patients who needed to be
treated with invasive MV had a poor prognosis with a three-fold increase in the risk of death.
Patients with AMI may have respiratory failure at presentation, or it may develop during
hospitalization due to acute heart failure, non-cardiac pulmonary disorders, or complications
of shock. Tsai et al. [1] previously demonstrated that in a STEMI population, 17% were admit-
ted with Killip class III symptoms. Furthermore, nearly 20% of patients who initially presented
with Killip class I or II symptoms, ultimately developed more advanced heart failure during
their hospitalization. In addition, factors unrelated to myocardial dysfunction may affect respi-
ratory function during MI and, hence, increase the need for MV. Kouraki et al. [4] demon-
strated that in 458 AMI patients treated with invasive MV, the initial reason for intubation was
non-cardiac in 13%. Further, during hospitalization, 17% of patients developed coma, 14% had
severe infections, 10% had sepsis, and 6% showed multiple organ dysfunction syndrome. More
recently, Lazzeri et al. [12] evaluated 106 patients with STEMI requiring invasive MV. In this
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Table 1. Baseline characteristics of the patients according to mechanical ventilation treatment.
Characteristics Pts. without MV
(n = 1,317)
Pts. with non-invasive MV
(n = 136)
Pts. with invasive MV
(n = 157)
P
Male (%) 955/1317 (73) 77/136 (57) 113/157 (72) 0.001
Pts. without MV vs Pts. with non-invasive MV 0.001
Pts. without MV vs Pts. with invasive MV >0.999
Pts. with non-invasive MV vs Pts. with
invasive MV
0.017
Age (years), mean ± SD 67±15 78±12 72±14 <0.001
Pts. without MV vs Pts. with non-invasive MV <0.001
Pts. without MV vs Pts. with invasive MV <0.001
Pts. with non-invasive MV vs Pts. with
invasive MV
<0.001
STEMI (%) 490/1237 (40) 41/136 (30) 75/157 (48) 0.009
Pts. without MV vs Pts. with non-invasive MV 0.070
Pts. without MV vs Pts. with invasive MV 0.160
Pts. with non-invasive MV vs Pts. with
invasive MV
0.005
BMI (kg/m2), mean ± SD 27±5 27±5 26± 5 0.54
Killip classification (%) <0.001
1 1117/1236 (90.4) 92/136 (67.6) 94/157 (59.9)
2 81/1236 (6.5) 23/136 (16.9) 24/157 (15.3)
3 22/1236 (1.8) 17/136 (12.6) 7/157 (4.4)
4 16/1236 (1.3) 4/136 (2.9) 32/157 (20.4)
Pts. without MV vs Pts. with non-invasive MV 0.002
Pts. without MV vs Pts. with invasive MV <0.001
Pts. with non-invasive MV vs Pts. with
invasive MV
0.066
TIMI Risk, STEMI patients 2.90±2.22 4.73±2.67 4.85±2.52 <0.001
Pts. without MV vs Pts. with non-invasive MV <0.001
Pts. without MV vs Pts. with invasive MV <0.001
Pts. with non-invasive MV vs Pts. with
invasive MV
>0.999
TIMI Risk, Non-STEMI patients 2.55±1.32 3.06±1.34 2.83±1.32 0.001
Pts. without MV vs Pts. with non-invasive MV 0.001
Pts. without MV vs Pts. with invasive MV 0.207
Pts. with non-invasive MV vs Pts. with
invasive MV
0.713
LVEF, mean ± SD 0.54 ± 0.12 0.47 ± 0.13 0.45 ± 0.15 <0.001
Pts. without MV vs Pts. with non-invasive MV <0.001
Pts. without MV vs Pts. with invasive MV <0.001
Pts. with non-invasive MV vs Pts. with
invasive MV
0.459
Troponin-I (ng/mL), 3.8 (0.58–19.3) 3.2 (0.7–14.0) 7.2 (0.9–2.7) 0.07
median (25th–75th percentile)
Coexisting conditions
Diabetes mellitus (%) 368/1292 (29) 54/136 (40) 63/156 (40) 0.001
Pts. without MV vs Pts. with non-invasive MV 0.031
Pts. without MV vs Pts. with invasive MV 0.012
Pts. with non-invasive MV vs Pts. with
invasive MV
>0.999
(Continued)
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Table 1. (Continued)
Characteristics Pts. without MV
(n = 1,317)
Pts. with non-invasive MV
(n = 136)
Pts. with invasive MV
(n = 157)
P
Smoking (%) 286/1314 (22) 18/136 (13) 34/157 (22) 0.066
COPD (%) 33/1316 (2.5) 8/136 (5.9) 5/157 (3.2) 0.128
Previous AMI (%) 203/1280 (15.9) 28/132 (21.2) 24/152 (15.8) 0.28
Previous stroke (%) 48/1310 (3.7) 13/136 (9.6) 8/157 (5.1) 0.005
Pts. without MV vs Pts. with non-invasive MV 0.066
Pts. without MV vs Pts. with invasive MV >0.999
Pts. with non-invasive MV vs Pts. with
invasive MV
0.439
Data are expressed as mean ± standard deviation (SD), median (25th–75th percentile), or number (%). P value was calculated for the comparison among
the three groups. MV, mechanical ventilation; BMI, body mass index; STEMI, ST-segment elevation myocardial infarction; LVEF, left ventricular ejection
fraction. TIMI, thrombolysis in myocardial infarction.
doi:10.1371/journal.pone.0151302.t001
Table 2. Medical treatment and coronary reperfusion according to mechanical ventilation treatment.
Characteristics Pts. without MV
(n = 1,317)
Pts. with non-invasive MV
(n = 136)
Pts. with invasive MV
(n = 157)
P
Pharmacotherapy during hospitalization
Aspirin (%) 1241/1309 (94.8) 124/136 (91.2) 137/157 (87.3) <0.001
Pts. without MV vs Pts. with non-invasive MV 0.444
Pts. without MV vs Pts. with invasive MV 0.017
Pts. with non-invasive MV vs Pts. with invasive MV 0.832
Thienopyridine (%) 1069/1289 (82.9) 95/134 (70.9) 88/146 (60.3) <0.001
Pts. without MV vs Pts. with non-invasive MV 0.009
Pts. without MV vs Pts. with invasive MV <0.001
Pts. with non-invasive MV vs Pts. with invasive MV 0.179
Beta-blocker (%) 1047/1308 (80,0) 97/136 (71,3) 88/157 (56,1) <0.001
Pts. without MV vs Pts. with non-invasive MV 0.092
Pts. without MV vs Pts. with invasive MV <0.001
Pts. with non-invasive MV vs Pts. with invasive MV 0.018
ACE inhibitor or ARB (%) 519/1310 (39.6) 72/136 (52.9) 50/157 (31.8) <0.001
Pts. without MV vs Pts. with non-invasive MV 0.009
Pts. without MV vs Pts. with invasive MV 0.148
Pts. with non-invasive MV vs Pts. with invasive MV 0.001
Reperfusion Therapy
Primary PCI or Fibrinolysis/STEMI patients (%) 394/485 (81.2) 28/41 (68.3) 51/75 (68.0) 0.008
Pts. without MV vs Pts. with non-invasive MV 0.251
Pts. without MV vs Pts. with invasive MV 0.059
Pts. with non-invasive MV vs Pts. with invasive MV >0.999
Primary PCI or Fibrinolysis/STEMI pts elegible for
reperfusion* (%)
343/369 (93.0) 27/34 (79.4) 44/50 (88.0) 0.039
Pts. without MV vs Pts. with non-invasive MV 0.027
Pts. without MV vs Pts. with invasive MV 0.665
Pts. with non-invasive MV vs Pts. with invasive MV 0.871
MV, mechanical ventilation; STEMI, ST-segment elevation myocardial infarction; ACE, angiotensin converting enzyme; ARB, angiotensin II receptor
blocker. PCI, percutaneous coronary intervention.
*STEMI patients on appropriate time window for reperfusion.
doi:10.1371/journal.pone.0151302.t002
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Table 3. Adjusted Cox proportional hazards regression model.
Variables HR 95% CI p
Lower Upper
Age (years) 1.04 1.02 1.06 <0.001
Killip classification 1.44 1.18 1.77 <0.001
Beta-blocker 0.47 0.29 0.75 0.001
ACE inhibitor or ARB 0.25 0.13 0.47 <0.001
Non-STEMI (reference)
STEMI patients without coronary reperfusion 2.09 1.13 3.89 0.019
STEMI patients with coronary reperfusion 1.10 0.62 1.95 0.736
Patients without mechanical ventilation (reference)
Patients with exclusively non-invasive mechanical ventilation 0.90 0.40 1.99 0.785
Patients with Invasive mechanical ventilation 3.07 1.79 5.26 <0.001
ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker; HR, hazard ratio. 95% CI, 95% confidence interval; STEMI, acute myocardial
infarction with ST-segment elevation. Adjusted for age, gender, diabetes, troponin levels, Killip classification on admission, left ventricular ejection fraction,
body mass index, acute myocardial infarction with ST-segment elevation, previous stroke, use of aspirin, thienopyridines, beta-blockers, angiotensin
converting enzyme inhibitors/angiotensin II receptor blockers and coronary reperfusion (for patients with acute myocardial infarction with ST-segment
elevation).
doi:10.1371/journal.pone.0151302.t003
Fig 1. Adjusted mortality curves by ventilation modality.
doi:10.1371/journal.pone.0151302.g001
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study, the incidence of MV was 7.6%, and the reasons for intubation included cardiogenic
shock in 64 patients (60.4%), ventricular fibrillation in 32 patients (30.1%), and acute pulmo-
nary edema in 10 patients (9.5%).
We demonstrated that compared to patients treated without MV, patients treated with inva-
sive or non-invasive MV had a higher Killip class at hospital admission and had lower levels of
LVEF. Interestingly, troponin peak levels were relatively modest and similar between groups.
This finding suggests that the differences in LVEF levels and heart failure symptoms between
groups were not linked with the extension of the acute myocardial necrosis. Additionally, we
found that advanced age was also associated with the use of both types of MV. Besides heart
failure, aging is particularly related to non-cardiac factors that may increase the risk of respira-
tory failure, such as dysphagia, delirium, and muscle weakness [13,14]. Recently, Lazerri et al.
[12] also observed that patients who received MV were older and more often had had a previ-
ous episode of AMI.
Our rate of invasive MV was similar to that previously reported [12]. We demonstrated that
AMI patients treated with invasive MV had a poor prognosis with a longer hospital length of
stay and high short-term mortality rates reaching almost 40%. Invasive MV was associated
with a three-fold increase in the risk of in-hospital death. These data are also similar to previ-
ous findings [3,4,12]. Whether this unfavorable prognosis was more related to cardiac or non-
cardiac complications (e.g., infections, septic shock, and pulmonary complications of MV) we
could not determine. In fact, a cause-and-effect relationship between invasive MV and clinical
outcomes could not be established, and our findings might have been influenced by complica-
tions of invasive MV such as ventilator-associated pneumonia, delirium and acute respiratory
distress syndrome [15,16,17,18]. Importantly, compared to patients treated without MV, the
use of cardiovascular pharmacotherapy was less common in the invasive MV subgroup and
reperfusion therapy was less common in both, invasive and non-invasive MV subgroups.
Whether these differences were related to drug contraindications associated to acute comorbid-
ities (e.g., bleeding, thrombocytopenia, hypotension, acute renal failure and hyperkalemia),
delayed admission that may have contraindicated reperfusion on STEMI patients, or presence
of type 2 AMI (secondary to ischemic imbalance), we could not determine. Nevertheless, con-
founders related to cardiovascular pharmacotherapy and coronary reperfusion were included
in our adjusted analysis.
On the other hand, clinical and randomized data on AMI patients treated with non-inva-
sive MV are significantly more limited. The efficacy and safety of non-invasive MV in AMI
have been tested in randomized small trials with patients who had cardiogenic pulmonary
edema of multiple etiologies besides myocardial ischemia. In these trials, compared with stan-
dard therapy, non-invasive MV reduced mortality and need for intubation [19–21]. Of note,
the effect was more prominent in trials in which myocardial ischemia or infarction was the
cause of pulmonary edema in higher proportions of patients [22]. More recently, one small
trial has specifically compared non-invasive MV between AMI and non-AMI patients [9].
This study showed comparable benefits in both groups in terms of hemodynamic and respira-
tory parameters, but was lacking in clinical outcomes data. In our study, we found that almost
10% of the entire population was treated with exclusively non-invasive MV and had relatively
favorable outcomes with moderate in-hospital mortality rates. Moreover, exclusively non-
invasive MV was not associated with in-hospital death in the adjusted analysis. Our findings
suggest that in real-world practice, non-invasive MV is common and may be safe in patients
with AMI.
Our study was limited in that it was a retrospective observational single-center study of a
relatively modestly sized population. Thus, despite all of the statistical adjustments, one cannot
account for the impact of unmeasured confounders on our outcomes. Additionally, we could
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not adjust our results by global risk scores, such as the APACHE II, by frailty scales, creatinine,
albumin or some other prognostic biomarkers since this information was not available in this
registry. Nonetheless, besides important clinical and treatment characteristics, we have
adjusted our results to troponin levels. This fact further strength our results, since troponin has
been considered the most important biomarker in AMI trials and correlates with the extent of
myocardial necrosis. It is known that in AMI, other biomarkers such as the B-type natriuretic
peptide and C-reactive protein might add prognostic information in selected patients. How-
ever, they are not routinely collected in clinical practice, or recommended by guidelines and
are not traditionally used in adjusted statistical models in AMI studies
Also, intention to treat analysis was not possible in this study, considering that we have no
information on the chronology of the use of invasive and non-invasive MV in those patients
that used both strategies. For instance, patients treated with the combination of both types of
MV were considered as part of the invasive MV group. This criterion was applied to identify
patients who were suitable to be exclusively treated by non-invasive strategies. Thus, we could
not identify patients whose clinical status failed to improve after the initial non-invasive treat-
ment and who subsequently needed invasive MV. We also did not have access to data on
malignant arrhythmias, defibrillation and cardio-pulmonary resuscitation. Despite the impor-
tance of these variables, it is unlikely that adjusting our results for them would change our find-
ings, considering that cardio-pulmonary resuscitation are often associated with other than
AMI etiologies of respiratory failure such as pulmonary edema, cardiogenic chock and systemic
infections. Lastly, information on the etiology, timing, and medical treatment of the respiratory
failure as well as MV duration were not available. Thus, we could not explore mechanisms of
respiratory failure and treatment aspects of this group of patients. Consequently, we could not
determine whether the high mortality in the invasive MV subgroup was more related to cardiac
or non-cardiac complications.
Likewise, we don’t have information about the reasons for lack of coronary reperfusion
among some patients in both groups treated with MV. It is possible that a significant part
of these patients was not in the appropriate time window for reperfusion. In fact, considering
only patients “eligible for reperfusion” (STEMI patients on appropriate time window for
reperfusion), reperfusion rates were considerably increased. Nevertheless, both treatment
groups had similar rates of reperfusion. Finally, we recognize that our findings do not
demonstrate a causality relation between invasive-MV and death. Based on the observational
nature of our study, we have only assessed an association between MV and outcomes,
and therefore, we could not adjust for unmeasured confounders. Thus, our findings are
hypothesis-generating that highlight the need of a large, well-powered, prospective trial
comparing the effectiveness of invasive and non-invasive MV in AMI patients with respira-
tory failure.
In conclusion, in AMI setting, 18% of the patients required MV. Almost half of these
patients were treated with exclusively non-invasive MV. This subgroup had a relatively favor-
able prognosis with moderate rates of short-term death. On the other hand, patients who
needed to be treated invasively had poor outcomes and a three-fold increase in the risk of in-
hospital death, compared to patients who did not use MV. Thus, future prospective random-
ized trials are needed to compare the effectiveness of invasive and non-invasive MV for the ini-
tial approach of respiratory failure in AMI patients.
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